Human Papillomavirus Prevalence and Genotypes in Head and Neck Cancers
Project no. 32534 · Status: Kapanmış (Yayın bekleniyor) · 2024
Summary
<p><strong style="color: rgb(0, 0, 0);">Objective: </strong><span style="color: rgb(0, 0, 0);">To determine the prevalence and genotype distribution of human papillomavirus (HPV) in</span></p><p><span style="color: rgb(0, 0, 0);">head and neck squamous cell carcinomas (HNSCC) and to evaluate the associations between</span></p><p><span style="color: rgb(0, 0, 0);">HPV positivity, clinicopathological characteristics, p16 expression, and p53 pattern.</span></p><p><strong style="color: rgb(0, 0, 0);">Materials and Methods: </strong><span style="color: rgb(0, 0, 0);">This prospective observational study was conducted at Ege University Faculty of Medicine between October 1, 2024, and April 15, 2026. A total of 160 patients who underwent surgery for suspected HNSCC were included. HPV DNA was analyzed in tumor tissue samples using polymerase chain reaction (PCR), and genotyping was performed in HPV-positive cases.</span></p><p><span style="color: rgb(0, 0, 0);">Demographic and clinicopathological data were recorded. p16 expression and p53 pattern</span></p><p><span style="color: rgb(0, 0, 0);">were evaluated by immunohistochemistry. Overall survival was analyzed using the Kaplan–</span></p><p><span style="color: rgb(0, 0, 0);">Meier method.</span></p><p><strong style="color: rgb(0, 0, 0);">Results: </strong><span style="color: rgb(0, 0, 0);">HPV DNA positivity was detected in 8 patients (5%). Among HPV-positive cases, HPV16</span></p><p><span style="color: rgb(0, 0, 0);">was identified in 50%, HPV18 in 25%, and HPV82 and HPV6 in the remaining cases. HPV</span></p><p><span style="color: rgb(0, 0, 0);">positivity was significantly higher in laryngeal tumors than in oral cavity tumors (p=0.027).</span></p><p><span style="color: rgb(0, 0, 0);">Smoking was more frequent in HPV-negative patients (p=0.013). p16 expression was more</span></p><p><span style="color: rgb(0, 0, 0);">common in HPV-positive tumors (p<0.001), and wild-type p53 pattern was associated with</span></p><p><span style="color: rgb(0, 0, 0);">HPV positivity (p=0.011). The sensitivity and specificity of p16 expression for predicting HPV</span></p><p><span style="color: rgb(0, 0, 0);">presence were 62.5% and 90.8%, respectively. No significant association was observed</span></p><p><span style="color: rgb(0, 0, 0);">between HPV positivity and overall survival (p>0.05). Absence of p16 expression, mutant</span></p><p><span style="color: rgb(0, 0, 0);">type p53 pattern, immunosuppression, and chronic disease were significantly associated with</span></p><p><span style="color: rgb(0, 0, 0);">mortality (p=0.015, p=0.027, p=0.035, and p=0.001, respectively).</span></p><p><strong style="color: rgb(0, 0, 0);">Conclusion: </strong><span style="color: rgb(0, 0, 0);">Although HPV prevalence was low, HPV positivity was significantly associated with p16</span></p><p><span style="color: rgb(0, 0, 0);">expression and wild-type p53 pattern. Combined evaluation of p16 and p53 patterns may</span></p><p><span style="color: rgb(0, 0, 0);">contribute to predicting HPV DNA-positive tumors.</span></p><p></p>